Circulating levels of triacylglycerol (TG) is a recognized risk factor for developing cardiovascular disease, a leading cause of death worldwide. The Institute of Medicine and the American Heart Association both recommend the consumption of n-3 polyunsaturated fatty acids (PUFA), specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), to reduce serum TG in hyperlipidemic individuals. Additionally, a number of systematic reviews have shown that individuals with any degree of dyslipidemia, elevated serum TG and/or cholesterol, may benefit from a 20-30 % reduction in serum TG after consuming n-3 PUFA derived from marine sources. Given that individuals with serum lipid levels ranging from healthy to borderline dyslipidemic constitute a large portion of the population, the focus of this review was to assess the potential for n-3 PUFA consumption to reduce serum TG in such individuals. A total of 1341 studies were retrieved and 38 clinical intervention studies, assessing 2270 individuals, were identified for inclusion in the current review. In summary, a 9-26 % reduction in circulating TG was demonstrated in studies where ≥ 4 g/day of n-3 PUFA were consumed from either marine or EPA/DHA-enriched food sources, while a 4-51 % reduction was found in studies where 1–5 g/day of EPA and/or DHA was consumed through supplements. Overall, this review summarizes the current evidence with regards to the beneficial effect of n-3 PUFA on circulating TG levels in normolipidemic to borderline hyperlipidemic, otherwise healthy, individuals. Thus demonstrating that n-3 PUFA may play an important role in the maintenance of cardiovascular health and disease prevention.

Cardiovascular disease (CVD) and non-alcoholic fatty liver disease (NAFLD) are manifestations of the metabolic syndrome. CVD remains the number one cause of mortality in the West, while NAFLD is the most common liver disease. Growing evidence suggests that polyunsaturated fatty acids (PUFA) influence risk factors including circulating lipids and inflammation on the development of CVD and NAFLD. N - 6 and n - 3 PUFA are comprised of distinct family members, which are increasingly recognized for their individual effects. Therefore, this review examines what is currently known about the specific effects of the major n - 3 and n - 6 PUFA on CVD and NAFLD. Overall, this review supports a beneficial effect of n - 3 PUFA and highlights distinctive effects between alpha-linolenic acid found in plant oils relative to marine derived eicosapentaenoic acid and docosahexaenoic acid. This review also highlights contrasting health effects between the n - 6 PUFA, linoleic and arachidonic acid.

BackgroundBreast cancer is attributable to modifiable risk factors including the intake of dietary n-3 polyunsaturated fatty acids (PUFA). A key piece of evidence, yet to be addressed, that would demonstrate a causal relationship between n-3 PUFA and breast cancer, is a dose-dependent effect of n-3 PUFA on tumour outcomes. Thus, the objective of the present study was to determine whether n-3 PUFA reduces mammary gland tumor outcomes in a dose-dependent manner in female MMTV-neu(ndl)-YD5 transgenic mice, an aggressive model of human breast cancer.MethodsHarems were provided one of three experimental diets comprised of 0, 3 or 9% (w/w) menhaden fish oil containing n-3 PUFA. Female offspring were weaned onto the same parental diet and maintained on their respective diet for 20 weeks. Tumour onset, size and multiplicity were measured throughout the study. Fatty acid composition of mammary gland and tumours were determined by gas–liquid chromatography.ResultsTumour size was significantly (p < 0.05) reduced in a dose-dependent manner. n-3 PUFA were also incorporated in a dose-dependent manner; differential incorporation was observed for eicosapentaenoic and docosapentaenoic acids into mammary gland tissue, while docosahexaenoic acid was preferentially incorporated into tumours.ConclusionOverall, the present study provides fundamental knowledge about the dose-dependent effect of n-3 PUFA on tumour outcomes in a pre-clinical model and also sheds light on the differential role of individual n-3 PUFA on tumour outcomes.

The current research was designed to determine the effect of phytase and glucanase on the energy value of corn and soybean meal (SBM) separately for broilers at various ages. The treatments were arranged as a 2 x 2 x 2 factorial, with 0 or 500 phytase units/kg or with 0 or 500 units of glucanase/kg, supplemented to either corn or SBM, with each combination represented by 6 cages of 10 birds. Diets of pure corn and soybean meal were not supplemented with additional nutrients, and were fed for 3-d periods beginning at 7, 14, or 21 d of age, representing the immature, transitional, and mature digestive tract, respectively. Each experiment was performed on a different group of birds from the same hatch. At the end of each experimental period, the broilers were euthanized and the contents of the ileum, duodenum and jejunum (pooled), and pancreas were removed for analysis. The ileal samples were analyzed for acid-insoluble ash and gross energy to determine the ileal-digestible energy (IDE) of the feedstuffs. The pancreas and duodenal-jejunal samples were analyzed for proteolytic and amylase activity to determine the influence of practical levels of phytate on enzyme activity. Results showed that neither phytase nor glucanase influenced enzyme activity in the digesta or pancreas, suggesting that practical levels of phytate did not influence the activity of proteolytic enzymes or amylase. Phytase did not influence the IDE value of either corn or SBM, and improved DM digestibility of the feed only for corn fed at 21 to 23 d. Glucanase improved IDE in both the corn and SBM diets at all ages, and improved DM digestibility in corn diets at all ages and SBM diets fed at 14 to 16 d. The IDE and DM digestibility of corn and the digesta and pancreatic enzyme activities increased with age, whereas the IDE of SBM was similar among age groups. The relative effect of glucanase on IDE of both feedstuffs was similar among age groups.

No abstract